Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Other Non Operating Income: 2021-2025

Historic Other Non Operating Income for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to $765,881.

  • SAB Biotherapeutics' Other Non Operating Income rose 1.49% to $765,881 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 27.26%. This contributed to the annual value of $2.5 million for FY2024, which is 463.70% up from last year.
  • As of Q3 2025, SAB Biotherapeutics' Other Non Operating Income stood at $765,881, which was up 159.07% from $295,630 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Other Non Operating Income peaked at $7.8 million during Q1 2022, and registered a low of -$69,138 during Q2 2021.
  • Over the past 3 years, SAB Biotherapeutics' median Other Non Operating Income value was $475,130 (recorded in 2024), while the average stood at $499,537.
  • As far as peak fluctuations go, SAB Biotherapeutics' Other Non Operating Income tumbled by 61.37% in 2022, and later soared by 6,264.31% in 2023.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Other Non Operating Income stood at $3,953 in 2021, then tumbled by 61.37% to $32,227 in 2022, then skyrocketed by 948.52% to $337,906 in 2023, then skyrocketed by 153.03% to $854,997 in 2024, then increased by 1.49% to $765,881 in 2025.
  • Its Other Non Operating Income stands at $765,881 for Q3 2025, versus $295,630 for Q2 2025 and $546,627 for Q1 2025.